» Articles » PMID: 22406545

EMT As the Ultimate Survival Mechanism of Cancer Cells

Overview
Specialty Oncology
Date 2012 Mar 13
PMID 22406545
Citations 258
Authors
Affiliations
Soon will be listed here.
Abstract

Epithelial cancers make up the vast majority of cancer types and, during the transition from benign adenoma to malignant carcinoma and metastasis, epithelial tumor cells acquire a de-differentiated, migratory and invasive behavior. This process of epithelial-mesenchymal transition (EMT) goes along with dramatic changes in cellular morphology, the loss and remodeling of cell-cell and cell-matrix adhesions, and the gain of migratory and invasive capabilities. EMT itself is a multistage process, involving a high degree of cellular plasticity and a large number of distinct genetic and epigenetic alterations, as fully differentiated epithelial cells convert into poorly differentiated, migratory and invasive mesenchymal cells. In the past years, a plethora of genes have been identified that are critical for EMT and metastasis formation. Notably, the EMT process not only induces increased cancer cell motility and invasiveness but also allows cancer cells to avoid apoptosis, anoikis, oncogene addiction, cellular, senescence and general immune defense. Notably, EMT seems to play a critical role in the generation and maintenance of cancer stem cells, highly consistent with the notion that metastatic cells carry the ability to initiate new tumors.

Citing Articles

Progress in the study of anti-tumor effects and mechanisms of vitexin.

Yang Q, Huan R, Meng D, Qi J, Xia L Pharmacol Rep. 2024; 77(1):124-134.

PMID: 39477892 DOI: 10.1007/s43440-024-00664-8.


Modeling epithelial-mesenchymal transition in patient-derived breast cancer organoids.

Bar-Hai N, Ben-Yishay R, Arbili-Yarhi S, Herman N, Avidan-Noy V, Menes T Front Oncol. 2024; 14:1470379.

PMID: 39469640 PMC: 11513879. DOI: 10.3389/fonc.2024.1470379.


YBX1 promotes epithelial-mesenchymal transition in hepatocellular carcinoma via transcriptional regulation of PLRG1.

Kwon J, Kim S Med Oncol. 2024; 41(11):280.

PMID: 39400789 DOI: 10.1007/s12032-024-02516-0.


The synergistic mechanisms of propofol with cisplatin or doxorubicin in human ovarian cancer cells.

Sue S, Tseng W, Wu Z, Huang S, Chen J, Wu Z J Ovarian Res. 2024; 17(1):187.

PMID: 39272193 PMC: 11401282. DOI: 10.1186/s13048-024-01509-x.


Disruption of perinatal myeloid niches impacts the aging clock of pancreatic β cells.

OSell J, Cirulli V, Pardike S, Aare-Bentsen M, Sdek P, Anderson J iScience. 2024; 27(9):110644.

PMID: 39262794 PMC: 11388196. DOI: 10.1016/j.isci.2024.110644.